Biomedical research on Alzheimer’s disease (AD), breast cancer (BC) and prostate cancer (PC) has globally improved our understanding of the etiopathological mechanisms underlying the onset of these diseases, often with the goal to identify associated genetic and environmental risk factors and develop new medicines. Being able to retrospectively monitor the major scientific breakthroughs and impact of such investment endeavors is important to re-address funding strategies if and when needed. The EU has supported research into those diseases via its successive framework programmes for research, technological development and innovation. The European Commission (EC) has already undertaken several activities to monitor research impact. As an additional contribution, the EC Joint Research Centre (JRC) launched in 2020 a survey addressed to former and current participants of EU-funded research projects in the fields of AD, BC and PC, with the aim to understand how EU-funded research has contributed to scientific innovation and societal impact. Further feedback was also gathered through in-depth interviews. A comprehensive analysis of survey replies, complemented with the information derived from the interviews, has recently been published in a Synopsis report. Here we discuss the main findings of this analysis and propose a set of priority actions that could be considered to help improving the translation of scientific innovation of biomedical research into societal impact.

PISTOLLATO Francesca;  CAMPIA Ivana;  DASKALOPOULOS Evangelos;  BERNASCONI Camilla;  DESAINTES Christian;  DI VIRGILIO Sergio;  KYRIAKOPOULOU Christina;  WHELAN Maurice;  DECEUNINCK Pierre; 

2023-07-03

BMC

JRC130561

1478-4505 (online),   

https://doi.org/10.1186/s12961-023-00981-z,    https://publications.jrc.ec.europa.eu/repository/handle/JRC130561,   

10.1186/s12961-023-00981-z (online),